Dernek Hakkında Tıbbi Onkoloji Derneği Haberler

The New England Journal of Medicine - Ekim 2010

ORIGINAL ARTICLE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

E.L. Kwak and Others
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally bioavailable ALK kinase inhibitor, produced a 57% response rate in this subgroup, with mild grade 1 or 2 toxic effects.
 
Brief Report: EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Y.L. Choi and Others
 
Brief Report: Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
J.E. Butrynski and Others